Dr. Vahan Kassabian presents findings in San Francisco and Orlando
Georgia Urology, the largest urology practice in the Southeast, remains on the forefront of advanced prostate cancer treatment and treatment research. Dr. Vahan Kassabian recently presented research findings at a pair of high-profile professional conferences: the 2018 American Society of Clinical Oncology Genitourinary Centers Symposium in San Francisco, Calif. and the 82nd Annual Meeting of the Southeastern Section of the American Urological Association (SESAUA) in Orlando, Fla. These presentations took place in February and March, respectively.
The study, conducted by Dr. Kassabian and his Georgia Urology colleagues –Drs. Jeffrey Proctor, Jerry Yuan, Allen Futral, and Ronald Anglade– explores the impact of a specific type of genomic testing, which assesses tumor biology for those facing advanced prostate cancer.
“The physicians at Georgia Urology realize our responsibility to patients reaches beyond the examining and operating rooms,” Dr. Kassabian said, “and I take great pride in sharing our findings with fellow physicians from around the country.”
If a prostate cancer patient experiences a recurrence of the disease after surgery or radiation treatment, it is considered advanced prostate cancer. This means cancer has spread outside the prostate gland. The cancer may find its way to nearby tissues, lymph nodes, bones, or other parts of the body.
Although it is not curable at this time, Georgia Urology’s specialists guide advanced prostate cancer patients through an individualized plan of action, including options such as hormone therapy and chemotherapy. These treatments may greatly extend life and reduce symptoms.
“We’re constantly discerning the evolution of best practices when it comes to advanced prostate cancer treatment,” Dr. Kassabian continued, “not only for the benefit of our own patients, but for all who are dealing with this challenging disease.”